Navigation Links
Dow AgroSciences, Sangamo BioSciences Announce the Achievement of Key Milestone in Plant Agriculture Collaboration
Date:2/12/2008

CEO of Dow AgroSciences Announces Milestone in Wall Street Presentation

INDIANAPOLIS, and RICHMOND, Calif., Feb. 12 /PRNewswire-FirstCall/ -- Dow AgroSciences LLC and Sangamo BioSciences, Inc. (Nasdaq: SGMO) today announced the successful completion of a key research milestone as part of their joint Research and Commercial License Agreement. This milestone represents the successful application of Sangamo's zinc finger DNA-binding protein nuclease (ZFN(TM)) technology in precision genome editing of a native plant gene with the aim of improving a valuable trait in canola, a crop central to Dow AgroSciences' business.

"It is my pleasure to announce we have achieved another significant milestone in the validation of zinc finger protein capabilities in plants," stated Jerome Peribere, the president and CEO of Dow AgroSciences, during his presentation at the Goldman Sachs Twelfth Annual Agricultural Biotech Forum. "We have demonstrated the robust utility and flexibility of the Sangamo technology in precision editing of a native plant gene, confirming the power of zinc finger proteins to accomplish specific and targeted modifications of the plant's own genetic sequence. The technology shows potential to enable the delivery of 'designer' crops into new and existing markets."

The milestone is the first demonstration of the precise modification of the DNA sequence of an existing gene in canola designed to generate an improved trait. This further demonstrates the ability of ZFNs to act at their intended target in crops of commercial importance.

"Sangamo's technology is revolutionizing scientists' ability to modify genes in cells. The power of the ZFP platform is being harnessed by Sangamo in therapeutics, our partner Sigma-Aldrich in research reagents, and, as we heard today, by Dow AgroSciences in plant agriculture to positively effect changes in plant genomes at a speed, efficiency, and specificity which heretofore was only considered a dream," said Edward Lanphier, Sangamo's president and CEO. "Dow AgroSciences has the expertise to implement our technology successfully into its precision trait development program."

The three-year agreement initiated October 2005 provides Dow AgroSciences with access to Sangamo's proprietary ZFP technology for the development of products in plants and plant cell cultures. During the initial three-year research term, Dow AgroSciences has the option to obtain a commercial license to sell products incorporating or derived from plant cells generated using Sangamo's ZFP technology, including agricultural crops, industrial products and plant-derived biopharmaceuticals.

Sangamo has also developed sequence-specific ZFNs for precision gene modification and targeted gene insertion. These technologies have the potential to play a major role in bringing new discoveries in genomics forward to the marketplace. The use of Sangamo's ZFP technology to enable the efficient and reproducible generation of combinations or stacks of multiple traits and the insertion of new traits could address increasing demand.

About Dow AgroSciences LLC

Dow AgroSciences LLC, based in Indianapolis, Indiana, USA, is a top-tier agricultural company that combines the power of science and technology with the "Human Element" to constantly improve what is essential to human progress. Dow AgroSciences provides innovative technologies for crop protection, pest and vegetation management, seeds, traits, and agricultural biotechnology to serve the world's growing population. Global sales for Dow AgroSciences, a wholly owned subsidiary of The Dow Chemical Company, are $3.8 billion. Learn more at http://www.dowagro.com.

About Sangamo BioSciences, Inc.

Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The most advanced ZFP Therapeutic(TM) development program is currently in Phase 2 clinical trials for evaluation of safety and clinical effect in patients with diabetic neuropathy. Phase 1 clinical trials are ongoing to evaluate a ZFP Therapeutic for peripheral artery disease. Other therapeutic development programs are focused on stem cell mobilization, ALS, cancer, HIV/AIDS, neuropathic pain, nerve regeneration, Parkinson's disease and monogenic diseases. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TF(TM)) that can control gene expression and, consequently, cell function. Sangamo is also developing sequence-specific ZFP Nucleases (ZFN(TM)) for gene modification. Sangamo has established strategic partnerships with companies outside of the human therapeutic space including Dow AgroSciences, Sigma-Aldrich Corporation and several companies applying its ZFP Technology to enhance the production of protein pharmaceuticals. For more information about Sangamo, visit the company's web site at http://www.sangamo.com.

This press release may contain forward-looking statements based on Dow AgroSciences LLC and Sangamo BioScience, Inc.'s current expectations. These forward-looking statements include, without limitation, references to the achievement of additional milestones under the Research and Commercial License Agreement, the anticipated execution of commercial and collaborative agreement with Dow AgroSciences, the application of Sangamo's ZFP TFs and ZFNs in plant agriculture, and the impact of milestone achievements on regulatory process and commercialization of new crop products. Actual results may differ materially from these forward-looking statements due to a number of factors, including technological challenges, Dow AgroSciences ability to develop commercially viable products and technological developments by our competitors. See the company's SEC filings, and in particular, the risk factors described in the company's Annual Report on Form 10-K and its most recent Quarterly report on Form 10-Q. Dow AgroSciences and Sangamo BioSciences, Inc. assume no obligation to update the forward-looking information contained in this press release.

(TM)Trademark of Sangamo Biosciences, Inc.


'/>"/>
SOURCE Sangamo BioSciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Sangamo BioSciences to Present at the BIO CEO & Investor Conference
2. Sangamo BioSciences Announces Fourth Quarter and Year-End 2007 Conference Call and Webcast
3. Sangamo BioSciences to Webcast Presentations at Investor and Analyst Briefing
4. Sangamo BioSciences to Present at the BMO Capital Markets Health Care Conference
5. Sangamo BioSciences to Present at the Piper Jaffray Health Care Conference
6. Sangamo BioSciences Announces ZFP Therapeutic Data From Nerve Regeneration Program at Society for Neuroscience Meeting
7. Sangamo BioSciences Announces Third Quarter 2007 Conference Call and Webcast
8. Sangamo BioSciences to Present at the 2007 BIO InvestorForum
9. Sangamo BioSciences to Present at the UBS Global Life Sciences Conference
10. Sangamo BioSciences Presents Data Demonstrating In Vivo Protection Against HIV Infection by CCR5-ZFN Therapeutic
11. Ardea Biosciences to Present at Roth Capital Partners 20th Annual OC Growth Stock Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/13/2017)... Research and Markets has announced the addition of the "Global ... ... CAGR of 16.83% during the period 2017-2021. The report ... market for 2017-2021. To calculate the market size, the report considers the ... also includes a a discussion of the key vendors operating in this ...
(Date:1/12/2017)... ... January 12, 2017 , ... ... Vertebral Technologies, Inc., announces the successful outcome of the first lumbar fusion ... VTI (Vertebral Technologies, Inc.) has partnered with Mexico-based medical product company BioMedical ...
(Date:1/12/2017)... Colo (PRWEB) , ... January 12, 2017 , ... ... then to targeted treatments, 26-year-old Lisa Rosendahl’s doctors gave her only a few ... describes a new drug combination that has stabilized Rosendahl’s disease and increased both ...
(Date:1/12/2017)... PUNE, India , January 12, 2017 The report "Direct-Fed ... Aquatic Animals), Form (Dry and Liquid), and Region - Global Forecast to 2022", ... 934.5 Million in 2016 and projected to reach USD 1,399.6 Million by 2022, ... Reading ... MarketsandMarkets Logo ...
Breaking Biology Technology:
(Date:12/20/2016)... and GENEVA, Dec, 20, 2016   Valencell , ... technology, and STMicroelectronics (NYSE: STM), a global ... electronics applications, announced today the launch of a ... biometric wearables that includes ST,s compact SensorTile ... Benchmark™ biometric sensor system. Together, SensorTile and ...
(Date:12/16/2016)... 16, 2016   IdentyTechSolutions America LLC , ... and solutions and a cutting-edge manufacturer of software ... is offering seamless, integrated solutions that comprise IDT ... The solutions provide IdentyTech,s customers with combined physical ... from crime and theft. "We are ...
(Date:12/16/2016)... Dec. 16, 2016 The global wearable medical device market, ... by 2021 from USD 5.31 billion in 2016, at a CAGR ... ... by technological advancements in medical devices, launch of a growing number ... wireless connectivity among healthcare providers, and increasing focus on physical fitness. ...
Breaking Biology News(10 mins):